/PNT

PNT Stock - POINT Biopharma Global Inc.

Q: What is the analyst price target for PNT?

Analyst price target information is not currently available for PNT.

Q: What is PNT's market cap?

Market capitalization information is not currently available for PNT.

Healthcare|Biotechnology|NASDAQ

$12.50+0.16%

+$0.02 (+0.16%) • Dec 26

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+18.4%upside

Target: $14.80

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for PNT

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-0.00

52W High$14.35

52W Low$6.57

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019
Revenue	$226.58M	N/A	N/A	N/A
Gross Profit	$226.58M	N/A	N/A	N/A
Gross Margin	100.0%	N/A	N/A	N/A
Operating Income	$125.52M	$-45,511,830	$-13,114,805	$-36,116
Net Income	$98.29M	$-45,902,481	$-13,373,003	$-36,896
Net Margin	43.4%	N/A	N/A	N/A
EPS	$1.04	$-0.62	$-0.34	$0.00

Company Overview

POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

9 Bullish0 Neutral/Bearish

Price Targets

$18

Average Target

↑ 40.0% Upside

Now

$10

Low

$18

Average

$22

High

Based on 8 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
July 20th 2023	Jefferies	Resumed	Buy	$14← $12
December 14th 2022	Raymond James	Initiation	Outperform	$10
November 30th 2022	SVB Leerink	Initiation	Outperform	$14
October 11th 2022	Oppenheimer	Initiation	Outperform	$20
September 16th 2022	Truist	Initiation	Buy	$22
September 14th 2022	Berenberg	Initiation	Buy	$20
August 16th 2022	Guggenheim	Initiation	Buy	$20
July 6th 2022	William Blair	Initiation	Outperform	-
May 26th 2022	Jefferies	Upgrade	Buy	$20← $7

Earnings History & Surprises

PNT

Beat Rate

70%

Last 10 quarters

Avg Surprise

+74.5%

EPS vs Estimate

Beats / Misses

7/3

Last 12 quarters

Latest EPS

$-0.23

Q4 2023

EPS Surprise History

Q1 22

+20.0%

$-0.16vs$-0.20

Q2 22

+10.0%

$-0.18vs$-0.20

Q3 22

-22.7%

$-0.27vs$-0.22

Q4 22

+7.1%

$-0.26vs$-0.28

Q1 23

+688.5%

$1.53vs$-0.26

Q2 23

+50.0%

$-0.16vs$-0.32

Q3 23

+17.2%

$-0.24vs$-0.29

Q4 23

+23.3%

$-0.23vs$-0.30

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2023	Nov 13, 2023	$-0.30	$-0.23	+23.3%	✓ BEAT
Q3 2023	Aug 14, 2023	$-0.29	$-0.24	+17.2%	✓ BEAT
Q2 2023	May 15, 2023	$-0.32	$-0.16	+50.0%	✓ BEAT
Q1 2023	Mar 27, 2023	$-0.26	$1.53	+688.5%	✓ BEAT
Q4 2022	Nov 14, 2022	$-0.28	$-0.26	+7.1%	✓ BEAT
Q3 2022	Aug 12, 2022	$-0.22	$-0.27	-22.7%	✗ MISS
Q2 2022	May 13, 2022	$-0.20	$-0.18	+10.0%	✓ BEAT
Q1 2022	Mar 25, 2022	$-0.20	$-0.16	+20.0%	✓ BEAT
Q4 2021	Nov 12, 2021	$-0.17	$-0.19	-11.8%	✗ MISS
Q3 2021	Aug 13, 2021	$-0.11	$-0.15	-36.4%	✗ MISS
Q2 2021	Jun 9, 2021	—	$-0.33	—	—
Q2 2021	Apr 29, 2021	—	$-0.10	—	—
Q4 2020	Nov 2, 2020	—	$-0.06	—	—
Q3 2020	Aug 20, 2020	—	$-0.04	—	—

Frequently Asked Questions about PNT

What is PNT's current stock price?

POINT Biopharma Global Inc. (PNT) is currently trading at $12.50 per share. The stock has moved +0.16% today.

What is the analyst price target for PNT?

The average analyst price target for PNT is $14.80, based on 1 analyst.

What sector is POINT Biopharma Global Inc. in?

POINT Biopharma Global Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is PNT's market cap?

POINT Biopharma Global Inc. has a market capitalization of $1.33 billion, making it a small-cap company.

Does PNT pay dividends?

No, POINT Biopharma Global Inc. does not currently pay a dividend to shareholders.